Advertisement
Skip to Content

Allogene Therapeutics Inc ALLO Stock Quote

| Rating as of

NASDAQ: ALLO

Last close prices updated as of Feb 03, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 7.78
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 7.67  –  8.11
  • Year Range 5.41  –  17.49
  • Market Cap 1.1220 Bil
  • Volume / Avg 1.1 Mil /  2.0 Mil
  • Price / Sales 4,469.87
  • Price / Book 1.52
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ALLO

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ALLO

Company Profile ALLO

Business Description

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Contact
210 East Grand Avenue
South San Francisco, CA, 94080
Industry Biotechnology
Employees 356

FAQs for Allogene Therapeutics Inc Stock

No. ALLO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ALLO’s market cap is 1.12 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ALLO’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ALLO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ALLO’s historical performance against its industry peers and the overall market.